Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing — more than doubling its investment over the past five years.

The approval of Eli Lilly's Kisunla provides a new option for patients in the early stages of the incurable, memory-destroying ailment.